Skyrizi

Skyrizi Approved for Crohn’s Disease Treatment

AbbVie announced the FDA’s approval of Skyrizi as the first specific interleukin-23 inhibitor for treatment ...

JUNE 24, 2022

Extended Risankizumab Induction Needed for Some Patients

Some Crohn’s disease patients may require 24 weeks before experiencing a response to treatment with ...

DECEMBER 16, 2021

Load more